 41 PM / Updated 10 minutes ago BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin Reuters Staff 1 Min Read 
Jan 29 (Reuters) - Theravance Biopharma Inc: 
* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
* THERAVANCE BIOPHARMA INC - FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF NOVEMBER 13, 2018 
* THERAVANCE BIOPHARMA - ‍ FDA INDICATED IT DOES NOT CURRENTLY PLAN TO CONVENE AN ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR REVEFENACIN (TD-4208)​ Source text for Eikon: Further company coverage: